This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.
N. Lynn Henry, MD, PhD
This video highlights four abstracts from SABCS investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.
This video discusses chemotherapy decision-making in early-stage breast cancer, and reviews tools such as PREDICT 2.0 and the MammaPrint 70-gene assay that can help guide treatment.
The promise of pharmacogenetics is personalization of therapy for individuals through refinement of the risk/benefit profile of pharmaceuticals based on inherited gene mutations. Classic examples of the impact of pharmacogenetics in clinical practice include variants in dihydropyrimidine dehydrogenase and treatment with fluorouracil.
Younger women with breast cancer present important management challenges due in part to differences in both tumor biology and individual patient factors. In his article, Peppercorn provides a comprehensive overview of these issues with a particular focus on questions surrounding systemic therapy options.
In the United States, approximately 180,000 women are diagnosed with breast cancer annually.
One of the primary challenges in the treatment of patients with early-stage breast cancer is determining which patients will benefit from adjuvant chemotherapy. Traditionally, treatment decisions have been made based on a combination of tumor characteristics and patient and physician perspectives regarding risks and benefits. Recent technologic advances, including the development of gene-expression arrays, have led to the identification of molecular signatures that provide prognostic information in addition to the basic clinicopathologic features of individual tumors. While these new methods allow for more refined determination of prognosis for an individual patient, few data are available to support use of these new technologies in the clinic for treatment decision-making. At present, data from a single retrospective study are available to support the use of one assay, the 21-gene recurrence score, for decision-making regarding adjuvant chemotherapy. Large, multinational clinical trials are currently ongoing to evaluate the use of two of the multiparameter assays, although it will be many years before oncologists can apply the results of these trials in the clinic.
Bladder cancer is the fifth most common cancer diagnosed in the
United States. Prognosis for this disease is dependent on both tumor
stage and grade. Radical cystectomy has been the standard treatment
for muscle-invasive local disease; however, combined-modality approaches
with the use of chemotherapy are gaining momentum with
data suggesting survival improvement. Patients with metastatic disease
have poor long-term survival rates despite systemic multiagent chemotherapy.
A variety of agents, including newer cytotoxic drugs and biologically
targeted agents, are under investigation to determine the most
effective regimen. The special needs of specific patient populations,
such as the elderly, those with a suboptimal performance status, and
patients with medical comorbidities have gained more attention.
Progress in the treatment of this disease is dependent on supporting
ongoing and future clinical trials.